New drug aims to keep myeloma in check after CAR-T
NCT ID NCT06138275
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests whether the drug elranatamab can lower the chance of multiple myeloma worsening after treatment with idecabtagene vicleucel (a CAR-T cell therapy). The study will enroll 32 adults with relapsed or refractory multiple myeloma. Participants will receive elranatamab as a shot under the skin to see if it improves response rates and delays disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elranatamab (a drug given as an injection under the skin)
What this could lead to
If it works, this could offer a way to keep multiple myeloma from coming back longer after CAR-T therapy.
What could go wrong
This is a small, early-phase study (32 people) with no control group, so results may not apply broadly. Side effects from elranatamab are possible and not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth-Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••